In lung cancer, the BTK inhibitor ibrutinib effectively inhibits the proliferation of some epidermal growth factor receptor (EGFR) mutant lung cancer cells by inhibiting the autophosphorylation of EGFR [23]. This evidence concerns the gene BTK and lung carcinoma.